Skip to main content
TipRanks
Go Ultimate75% OFF

Shanghai Henlius Biotech, Inc. Class H (2696) Stock Price & Analysis

8 Followers

2696 Stock Chart & Stats

HK$48.12-HK$1.86(-3.72%)
At close: 4:00 PM GMT+8
HK$50HK$60HK$70Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 47.40 - HKD 50.00
52-Week Range
HKD 45.50 - HKD 87.10
Previous Close
HKD 49.98
Volume
N/A
Average Volume (3M)
780.15K
Market Cap
HKD 26.24B
Enterprise Value
HKD 38.71B
Total Cash (Recent Filing)
HKD 956.02M
Total Debt (Recent Filing)
HKD 3.95B
Price to Earnings (P/E)
25.7
Beta
0.66
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sustained Profitability

Sustained profitability and high gross margins indicate that Henlius has moved beyond a purely development-stage profile. This provides internal funding capacity for pipeline investment, supports commercial resilience, and strengthens the durability of earnings as biologic sales expand.

Positive Cash Generation

Consistently positive operating cash flow, together with positive free cash flow in recent years, demonstrates that commercialization is generating meaningful cash. This improves financial self-funding capacity and reduces reliance on external capital for ongoing operations and development.

Improving Balance Sheet

The substantial reduction in debt relative to equity improves balance-sheet resilience compared with prior years. Lower leverage should give Henlius greater flexibility to fund growth, manage development spending, and absorb execution setbacks while profitability continues to mature.

Bears Say

Margin Compression

The 2025 decline in net and operating profitability suggests that higher costs or investment levels are reducing earnings leverage. If this persists, revenue growth may translate less efficiently into profit and could weaken the company’s ability to compound earnings.

Meaningful Leverage

Although debt-to-equity has improved, meaningful and historically volatile leverage leaves Henlius more sensitive to development or commercialization setbacks. Debt obligations can constrain capital allocation and increase the financial impact of weaker operating performance.

Uneven Free Cash Flow

The history of negative free cash flow and the renewed decline in 2025 show that cash outcomes remain sensitive to investment requirements. This uneven conversion can limit dependable internal funding and create greater variability in financing needs over time.

Shanghai Henlius Biotech, Inc. Class H News

2696 FAQ

What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$45.50 and its highest was HK$87.10 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$26.24B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Shanghai Henlius Biotech, Inc. Class H released its earnings results on Aug 21, 2026. The company reported HK$0.924 earnings per share for the quarter, beating the consensus estimate of HK$0.503 by HK$0.421.
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 347,877,260 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.924 in its last earnings report, beating expectations of HK$0.503. Following the earnings report the stock price went down -2.488%.
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology